Insulin glargine: pharmacokinetic and pharmacodynamic basis of clinical effect
Glargine became the first long-acting insulin analogue. Glargine was designed to meet basal insulin requirements throughout the day with a single injection. Pharmacokinetics of insulin glargine is characterized by biotransformation into metabolites M1 and M2 that transforms the B chain of glargine s...
Saved in:
| Main Authors: | Vadim Valer'evich Klimontov, Natalya Evgen'evna Myakina |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2014-12-01
|
| Series: | Сахарный диабет |
| Subjects: | |
| Online Access: | https://www.dia-endojournals.ru/jour/article/view/6691 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
On the safety of insulin Glargine
by: Ivan Ivanovich Dedov, et al.
Published: (2009-09-01) -
Individualisation of basal insulin therapy of type 2 diabetes: evidence from large randomized controlled trials
by: S. V. Nedogoda, et al.
Published: (2023-01-01) -
Pharmacokinetics and pharmacodynamics of insulin lispro 25 versus the original preparation (Humalog®25) in Chinese healthy male volunteers
by: Mingxue Zhu, et al.
Published: (2025-02-01) -
Evaluation of biosimilarity of RinGlar® (GEROPHARM LLC, Russia) and Lantus® (Sanofi-Aventis Deutschland GmbH, Germany) using the euglycemic hyperinsulinemic clamp technique in patients with type 1 diabetes: double-blind randomized clinical trial
by: Alexander Y. Mayorov, et al.
Published: (2020-12-01) -
Metabolic and cardiovascular effects of early insulin glargin prescription: based on data from ORIGIN study
by: Elena Valer'evna Biryukova, et al.
Published: (2012-09-01)